New combo therapy shows promise for tough head and neck cancers
Disease control
Completed
This study tested whether adding the drug buparlisib to standard chemotherapy (paclitaxel) helps people with advanced head and neck cancer live longer. About 487 adults whose cancer had returned or spread and who had already tried other treatments took part. The goal was to see i…
Phase: PHASE3 • Sponsor: Adlai Nortye Biopharma Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC